Cargando…
A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 pro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293343/ https://www.ncbi.nlm.nih.gov/pubmed/34524728 http://dx.doi.org/10.1002/cmdc.202100458 |
_version_ | 1784749608328495104 |
---|---|
author | Brüschweiler, Sven Fuchs, Julian E. Bader, Gerd McConnell, Darryl B. Konrat, Robert Mayer, Moriz |
author_facet | Brüschweiler, Sven Fuchs, Julian E. Bader, Gerd McConnell, Darryl B. Konrat, Robert Mayer, Moriz |
author_sort | Brüschweiler, Sven |
collection | PubMed |
description | The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 promises to be an attractive therapeutic strategy to suppress cell proliferation and enhance cell apoptosis in cancer. Direct targeting of NRF2 with small‐molecules to discover protein‐DNA interaction inhibitors is challenging as it is a largely intrinsically disordered protein. To discover molecules that bind to NRF2 at the DNA binding interface, we performed an NMR‐based fragment screen against its DNA‐binding domain. We discovered several weakly binding fragment hits that bind to a region overlapping with the DNA binding site. Using SAR by catalogue we developed an initial structure‐activity relationship for the most interesting initial hit series. By combining NMR chemical shift perturbations and data‐driven docking, binding poses which agreed with NMR information and the observed SAR were elucidated. The herein discovered NRF2 hits and proposed binding modes form the basis for future structure‐based optimization campaigns on this important but to date ‘undrugged’ cancer driver. |
format | Online Article Text |
id | pubmed-9293343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92933432022-07-20 A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods Brüschweiler, Sven Fuchs, Julian E. Bader, Gerd McConnell, Darryl B. Konrat, Robert Mayer, Moriz ChemMedChem Full Papers The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 promises to be an attractive therapeutic strategy to suppress cell proliferation and enhance cell apoptosis in cancer. Direct targeting of NRF2 with small‐molecules to discover protein‐DNA interaction inhibitors is challenging as it is a largely intrinsically disordered protein. To discover molecules that bind to NRF2 at the DNA binding interface, we performed an NMR‐based fragment screen against its DNA‐binding domain. We discovered several weakly binding fragment hits that bind to a region overlapping with the DNA binding site. Using SAR by catalogue we developed an initial structure‐activity relationship for the most interesting initial hit series. By combining NMR chemical shift perturbations and data‐driven docking, binding poses which agreed with NMR information and the observed SAR were elucidated. The herein discovered NRF2 hits and proposed binding modes form the basis for future structure‐based optimization campaigns on this important but to date ‘undrugged’ cancer driver. John Wiley and Sons Inc. 2021-10-08 2021-12-06 /pmc/articles/PMC9293343/ /pubmed/34524728 http://dx.doi.org/10.1002/cmdc.202100458 Text en © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Full Papers Brüschweiler, Sven Fuchs, Julian E. Bader, Gerd McConnell, Darryl B. Konrat, Robert Mayer, Moriz A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title | A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title_full | A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title_fullStr | A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title_full_unstemmed | A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title_short | A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods |
title_sort | step toward nrf2‐dna interaction inhibitors by fragment‐based nmr methods |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293343/ https://www.ncbi.nlm.nih.gov/pubmed/34524728 http://dx.doi.org/10.1002/cmdc.202100458 |
work_keys_str_mv | AT bruschweilersven asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT fuchsjuliane asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT badergerd asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT mcconnelldarrylb asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT konratrobert asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT mayermoriz asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT bruschweilersven steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT fuchsjuliane steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT badergerd steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT mcconnelldarrylb steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT konratrobert steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods AT mayermoriz steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods |